We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Health Canada has accepted a marketing authorisation application for the Belgian pharmaceutical company Mithra’s complex therapeutic Tibelia, a tibolone-based product, to be used in hormone therapy (HT).